{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:26Z","timestamp":1761100526287},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2000,11,1]]},"DOI":"10.1038\/sj.leu.2401921","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T18:27:43Z","timestamp":1031164063000},"page":"1954-1959","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A phase I\/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation"],"prefix":"10.1038","volume":"14","author":[{"given":"E","family":"Olavarria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Eades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Timms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2000,11,2]]},"reference":[{"key":"BF2401921_CR1","first-page":"491","volume":"17","author":"T Demirer","year":"1996","unstructured":"Demirer T, Buckner CD, Appelbaum F, Bensinger WI, Sanders J, Lambert K, Clift R, Fefer A, Storb R, Slattery JT . Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels Bone Marrow Transplant 1996 17: 491\u2013495","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/10428199609054777","volume":"22","author":"M Hassan","year":"1996","unstructured":"Hassan M, Ehrsson H, Ljungman P . Aspects concerning busulfan pharmacokinetics and bioavailability Leuk Lymphoma 1996 22: 395\u2013407","journal-title":"Leuk Lymphoma"},{"key":"BF2401921_CR3","first-page":"2363","volume":"14","author":"G Vassal","year":"1994","unstructured":"Vassal G . Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls Anticancer Res 1994 14: 2363\u20132370","journal-title":"Anticancer Res"},{"key":"BF2401921_CR4","first-page":"31","volume":"16","author":"JT Slattery","year":"1995","unstructured":"Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR . Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31\u201342","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bmt.1701001","volume":"20","author":"AB Pawlowska","year":"1997","unstructured":"Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B . Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia Bone Marrow Transplant 1997 20: 915\u2013920","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR6","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R . Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225\u2013230","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","volume":"20","author":"JT Slattery","year":"1998","unstructured":"Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20: 543\u2013549","journal-title":"Ther Drug Monit"},{"key":"BF2401921_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.bmt.1701322","volume":"22","author":"US Schuler","year":"1998","unstructured":"Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G . Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation Bone Marrow Transplant 1998 22: 241\u2013244","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","volume":"20","author":"P Ljungman","year":"1997","unstructured":"Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G . High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909\u2013913","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR10","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","volume":"84","author":"PJ Shaw","year":"1994","unstructured":"Shaw PJ, Scharping CE, Brian RJ, Earl JW . Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia Blood 1994 84: 2357\u20132362","journal-title":"Blood"},{"key":"BF2401921_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.1993.108","volume":"54","author":"MB Regazzi","year":"1993","unstructured":"Regazzi MB, Locatelli F, Buggia I, Bonetti F, Zecca M, Pregnolato M, Quaglini S . Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation Clin Pharmacol Ther 1993 54: 45\u201352","journal-title":"Clin Pharmacol Ther"},{"key":"BF2401921_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00688324","volume":"37","author":"G Vassal","year":"1996","unstructured":"Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle J, Gouyette A, Hartmann O . Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation Cancer Chemother Pharmacol 1996 37: 247\u2013253","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401921_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0378-4347(98)00019-X","volume":"709","author":"MH Quernin","year":"1998","unstructured":"Quernin MH, Poonkuzhali B, Montes C, Krishnamoorthy R, Dennison D, Srivastava A, Vilmer E, Chandy M, Jacqz-Aigrain E . Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol J Chromatogr B Biomed Sci Appl 1998 709: 47\u201356","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BF2401921_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1046\/j.1365-2141.2000.01905.x","volume":"108","author":"E Olavarria","year":"2000","unstructured":"Olavarria E, Kanfer E, Szydlo R, O'Brien S, Craddock C, Apperley J, Goldman JM . High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single centre experience Br J Haematol 2000 108: 769\u2013777","journal-title":"Br J Haematol"},{"key":"BF2401921_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1177\/106002809402800911","volume":"28","author":"I Buggia","year":"1994","unstructured":"Buggia I, Locatelli F, Regazzi MB, Zecca M . Busulfan Ann Pharmacother 1994 28: 1055\u20131062","journal-title":"Ann Pharmacother"},{"key":"BF2401921_CR16","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","volume":"84","author":"M Hassan","year":"1994","unstructured":"Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Stary J, Wallin I, Kallberg N . Busulfan bioavailability Blood 1994 84: 2144\u20132150","journal-title":"Blood"},{"key":"BF2401921_CR17","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood.V93.12.4436","volume":"93","author":"JP Gibbs","year":"1999","unstructured":"Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, Slattery JT . The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 4436\u20134440","journal-title":"Blood"},{"key":"BF2401921_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","volume":"20","author":"JT Slattery","year":"1998","unstructured":"Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20: 543\u2013549","journal-title":"Ther Drug Monit"},{"key":"BF2401921_CR19","first-page":"759","volume":"14","author":"US Schuler","year":"1994","unstructured":"Schuler US, Schroer S, Kuhnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller KP, Ehninger G . Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994 14: 759\u2013765","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR20","first-page":"18","volume":"20","author":"LB Grochow","year":"1993","unstructured":"Grochow LB . Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 1993 20: (Suppl. 4) 18\u201325","journal-title":"Semin Oncol"},{"key":"BF2401921_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s002800050404","volume":"37","author":"HP Bhagwatwar","year":"1996","unstructured":"Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS . Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy Cancer Chemother Pharmacol 1996 37: 401\u2013408","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401921_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/sj.bmt.1701458","volume":"22","author":"Z Hassan","year":"1998","unstructured":"Hassan Z, Nilsson C, Hassan M . Liposomal busulphan: bioavailability and effect on bone marrow in mice Bone Marrow Transplant 1998 22: 913\u2013918","journal-title":"Bone Marrow Transplant"},{"key":"BF2401921_CR23","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood.V85.11.3247.bloodjournal85113247","volume":"85","author":"G Ehninger","year":"1995","unstructured":"Ehninger G, Schuler U, Renner U, Ehrsam M, Zeller KP, Blanz J, Storb R, Deeg HJ . Use of a water-soluble busulfan formulation \u2013 pharmacokinetic studies in a canine model Blood 1995 85: 3247\u20133249","journal-title":"Blood"},{"key":"BF2401921_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s002800050847","volume":"42","author":"M Hassan","year":"1998","unstructured":"Hassan M, Hassan Z, Nilsson C, Rehim MA, Kumlien S, Elfsson B, Kallberg N . Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration Cancer Chemother Pharmacol 1998 42: 471\u2013478","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2401921.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2401921","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2401921.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:42:08Z","timestamp":1648762928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2401921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11,1]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2000,11,1]]}},"alternative-id":["BF2401921"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2401921","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11,1]]},"assertion":[{"value":"22 May 2000","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2000","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2000","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}